Med-Tech Innovation January 31, 2024
Carcinotech has raised $5.3 million of funding as the company looks to build on its traction in the UK and Europe, with US expansion planned later this year.
Carcinotech’s Carcino3D technology enables the manufacture of 3D printed micro-tumours, using cells derived from patient biopsies and blood samples to simulate the tumour microenvironment, accelerating ethical drug screening and the delivery of more effective cancer treatments to market.
Ishani Malhotra, CEO and founder of Carcinotech, said: “Our vision is to be at the forefront of cancer drug testing and provide personalised medicine testing to every individual suffering from cancer to improve their treatment and chance of survival. Working with global...
Today's Sponsors
Today's Sponsor